Skip to main content
Erschienen in: Journal of Neurology 6/2018

20.03.2018 | Original Communication

Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance

verfasst von: Olivia Samotus, Jack Lee, Mandar Jog

Erschienen in: Journal of Neurology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Botulinum toxin type A (BoNT-A) injections is the accepted first-line therapy for cervical dystonia (CD), however, numerous patients discontinue treatment early due to perceived sub-optimal relief. To improve BoNT-A therapy for CD, proper assessment of neck motion and selection of relevant muscles and dosing must be met. Kinematic technology may improve treatment outcomes by guiding physicians to better tailor muscle selection and BoNT-A dosing for CD therapy.

Methods

28 CD participants were placed into either group: expert injector determined injection patterns by visual assessment (“vb”) versus injection patterns based on kinematics interpreted by an expert injector (“kb”). Injections occurred at weeks 0, 16 and 32 with follow-ups at weeks 6, 22 and 38. Kinematics utilized four sensors to capture the severity of multiaxial, static neck posturing (e.g., torticollis) and dynamic, spasmodic/tremor movements while participants were seated. Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score changes were evaluated over 38 weeks.

Results

For the “kb” participants, there was a significant 28.8% (− 11.25 points) reduction in TWSTRS total score at week 6, as well as significant reduction in severity and disability TWSTRS sub-scores (parts I and II) with maintained improvement at subsequent visits. As for the “vb” participants had a significant reduction in total TWSTRS score by 28.5% (− 9.84 points) after week 22. Disability score for the “vb” group trended towards improvement over 38 weeks.

Conclusion

Clinical judgement guided by kinematic analysis of CD biomechanics can result in faster optimal muscle selections and minimize use of higher BoNT-A doses as compared to visual determination, thereby achieving comparable and potentially better treatment outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Molho ES, Stacy M, Gillard P et al (2016) Impact of cervical dystonia on work productivity: an analysis from a patient registry. Mov Disord Clin Pract 3(2):130–138CrossRefPubMed Molho ES, Stacy M, Gillard P et al (2016) Impact of cervical dystonia on work productivity: an analysis from a patient registry. Mov Disord Clin Pract 3(2):130–138CrossRefPubMed
3.
Zurück zum Zitat Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100 Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100
7.
Zurück zum Zitat Contarino MF, Smit M, Van den Dool J, Volkmann J, Tijssen MAJ (2016) Unmet needs in the management of cervical dystonia. Front Neurol 7(165):1–7 Contarino MF, Smit M, Van den Dool J, Volkmann J, Tijssen MAJ (2016) Unmet needs in the management of cervical dystonia. Front Neurol 7(165):1–7
8.
Zurück zum Zitat Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 349(1–2):84–93CrossRefPubMed Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 349(1–2):84–93CrossRefPubMed
10.
Zurück zum Zitat Trosch RM, Espay AJ, Truong D et al (2017) Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J Neurol Sci 376:84–90CrossRefPubMed Trosch RM, Espay AJ, Truong D et al (2017) Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J Neurol Sci 376:84–90CrossRefPubMed
11.
Zurück zum Zitat Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S (2016) Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263:1188–1194CrossRefPubMedPubMedCentral Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S (2016) Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263:1188–1194CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19(5):533–538CrossRefPubMed Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19(5):533–538CrossRefPubMed
13.
Zurück zum Zitat Evidente V, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor and Other Hyperkin Mov 2:1–10 Evidente V, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor and Other Hyperkin Mov 2:1–10
14.
Zurück zum Zitat Castelão M, Marques RE, Duarte GS et al (2017) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 12:CD003633PubMed Castelão M, Marques RE, Duarte GS et al (2017) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 12:CD003633PubMed
15.
Zurück zum Zitat Evidente VG, Fernandez HH, Ledoux MS et al (2013) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®) in cervical dystonia. J Neural Transm (Vienna) 120(12):1699–1707CrossRef Evidente VG, Fernandez HH, Ledoux MS et al (2013) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®) in cervical dystonia. J Neural Transm (Vienna) 120(12):1699–1707CrossRef
16.
Zurück zum Zitat De Bruijn E, Nijmeijer SWR, Forbes PA et al (2015) Improved identification of dystonic cervical muscles via abnormal muscle activity during isometric contractions. J of Neurol Sci 352(1–2):10–16CrossRef De Bruijn E, Nijmeijer SWR, Forbes PA et al (2015) Improved identification of dystonic cervical muscles via abnormal muscle activity during isometric contractions. J of Neurol Sci 352(1–2):10–16CrossRef
17.
Zurück zum Zitat Wu C, Xue F, Chang W (2016) Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. SpringerPlus 5(1):1292–1296CrossRefPubMedPubMedCentral Wu C, Xue F, Chang W (2016) Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. SpringerPlus 5(1):1292–1296CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Rahimi F, Samotus O, Lee J, Jog MS (2015) Effective management of upper limb parkinsonian tremor by IncobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor and Other Hyperkin Mov 5:1–13 Rahimi F, Samotus O, Lee J, Jog MS (2015) Effective management of upper limb parkinsonian tremor by IncobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor and Other Hyperkin Mov 5:1–13
19.
Zurück zum Zitat Samotus O, Rahimi F, Lee J, Jog M (2016) Functional ability improved in essential tremor by IncobotulinumtoxinA injections using kinematically determined biomechanical patterns—a new future. PLoS One 11(4):e0153739CrossRefPubMedPubMedCentral Samotus O, Rahimi F, Lee J, Jog M (2016) Functional ability improved in essential tremor by IncobotulinumtoxinA injections using kinematically determined biomechanical patterns—a new future. PLoS One 11(4):e0153739CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308(1–2):103–109CrossRefPubMed Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308(1–2):103–109CrossRefPubMed
21.
Zurück zum Zitat Naumann M, Yakovleff A, Durif F (2002) A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249(1):57–63CrossRefPubMed Naumann M, Yakovleff A, Durif F (2002) A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249(1):57–63CrossRefPubMed
22.
Zurück zum Zitat Samotus O, Lee J, Jog M (2017) Long- term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 12(6):e0178670CrossRefPubMedPubMedCentral Samotus O, Lee J, Jog M (2017) Long- term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 12(6):e0178670CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kim SD, Yiannikas C, Mahant N, Vucic S, Fung VSC (2014) Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord 29(6):835–838CrossRefPubMed Kim SD, Yiannikas C, Mahant N, Vucic S, Fung VSC (2014) Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord 29(6):835–838CrossRefPubMed
24.
Zurück zum Zitat Botox [Package Insert] 2010. Allergan Pharmaceuticals, Irvine, CA Botox [Package Insert] 2010. Allergan Pharmaceuticals, Irvine, CA
25.
Zurück zum Zitat Marion MH, Humberstone M, Grunewald R, Wimalaratna S (2016) British neurotoxin network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Prac Neurol 0:1–8 Marion MH, Humberstone M, Grunewald R, Wimalaratna S (2016) British neurotoxin network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Prac Neurol 0:1–8
27.
Zurück zum Zitat Albanese A, Romito LM, Calandrella D (2015) Therapeutic advances in dystonia. Mov Disord 30(11):1547–1556CrossRefPubMed Albanese A, Romito LM, Calandrella D (2015) Therapeutic advances in dystonia. Mov Disord 30(11):1547–1556CrossRefPubMed
28.
29.
Zurück zum Zitat Werdelin L, Dalager T, Fuglsang-Frederiksen A (2011) The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 122(11):2305–2309CrossRefPubMed Werdelin L, Dalager T, Fuglsang-Frederiksen A (2011) The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 122(11):2305–2309CrossRefPubMed
30.
Zurück zum Zitat Van Gerpen JA, Matsumoto JY, Ahlskog JE, Maraganore DM, McManis PG (2000) Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 23:1752–1756CrossRefPubMed Van Gerpen JA, Matsumoto JY, Ahlskog JE, Maraganore DM, McManis PG (2000) Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 23:1752–1756CrossRefPubMed
31.
Zurück zum Zitat Kilbane C, Ostrem J, Galifianakis N, Grace J, Markun L, Glass GA (2012) Multichannel electromyographic mapping to optimize OnabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (N.Y.) 2. pii: tre-02-91-598-1. https://doi.org/10.7916/D8XK8D8V Kilbane C, Ostrem J, Galifianakis N, Grace J, Markun L, Glass GA (2012) Multichannel electromyographic mapping to optimize OnabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (N.Y.) 2. pii: tre-02-91-598-1. https://​doi.​org/​10.​7916/​D8XK8D8V
32.
Zurück zum Zitat Pirio richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA (2017) Dystonia treatment: patterns of medication use in an international cohort. Neurology 88(6):543–550CrossRefPubMedPubMedCentral Pirio richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA (2017) Dystonia treatment: patterns of medication use in an international cohort. Neurology 88(6):543–550CrossRefPubMedPubMedCentral
Metadaten
Titel
Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance
verfasst von
Olivia Samotus
Jack Lee
Mandar Jog
Publikationsdatum
20.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-8819-6

Weitere Artikel der Ausgabe 6/2018

Journal of Neurology 6/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.